Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-10-17
2008-11-18
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07452910
ABSTRACT:
The invention relates to the use of N-substituted indole-3-glyoxylamides of the general Formula I:and to pharmaceutical compositions having antitumor action.
REFERENCES:
patent: 5405864 (1995-04-01), Broka
patent: 6008231 (1999-12-01), Lebaut et al.
patent: 6225329 (2001-05-01), Richter et al.
patent: 6232327 (2001-05-01), Nickel et al.
patent: 6251923 (2001-06-01), Hofgen et al.
patent: 6262044 (2001-07-01), Moller et al.
patent: 6344467 (2002-02-01), Lebaut et al.
patent: 6432987 (2002-08-01), Gunther et al.
patent: 6693119 (2004-02-01), Nickel et al.
patent: 2004/0266762 (2004-12-01), Gerlach
patent: 2006/0040991 (2006-02-01), Roessler
patent: 2006/0280787 (2006-12-01), Roessler et al
patent: 2315989 (1973-10-01), None
patent: 196 36 150 (1998-02-01), None
patent: 2000-239252 (2000-09-01), None
patent: WO-98/09946 (1998-03-01), None
patent: WO 99/46237 (1999-09-01), None
patent: WO 99/51224 (1999-10-01), None
patent: WO 99/55696 (1999-11-01), None
patent: WO 00/67802 (2000-11-01), None
Gura et al. (Science, 1997, 278:1041-1042.
Johnson et al. (British J. of Cancer, 2001, 84(10):1424-1431.
Dupont et al. J. Cutan. Med. Surg., 1998, vol. 2, pp. 146-152 (Abstract attached).
Caplus AN 1999:708761, Hofgen Norbert et al., RN 247584-34-5. (Abstract only).
Fiszer-Maliszewska et al., “Immunomodulation and Therapeutic Effects of Cytostatics,” Zbl. Bakt. Suppl. 13, pp. 215-230 (1985).
Lipp et al., “Some derivatives of 5-benzyloxy-3-indolylglyoxylic acid,” CA 52:18374 (1958).
Ooi Ve, Liu F., Curr. Med. Chem. Jul. 7, 2000(7):715-29, NCBI abstract.
Podwinski et al., “Synthesis of some 5-benzyloxyindole-3-glyoxylic acid amides,” CA 70(9):37598 (1969).
Bacher, et al., “D-24851, a Novel Synthetic Microtubule Inhibitor, Exerts Curative Antitumoral Activity in Vivo, Shows Efficacy toward Multidrug-resistant Tumor Cells, and Lacks Neurotoxicity,” Cancer Research, 61(1):392-399 (2001).
Evans et al., “Probing the 5-Ht3Receptor Site Using Novel Indole-3-Glyoxylic Acid Derivatives,” Med. Chem. Res., 3:386-406 (1993).
Guenther et al., “Discovery and synthesis of novel N-substituted indoly-3-glyoxylic acid derivatives with tublin-binding activity as anti-cancer agents,” Proceedings of the American Association for Cancer Research Annual Meeting, 41:769 (2000).
Raab et al., “ZIO-301 (Indibulin) a novel tubulin polymerization inhibitor has potent anti-tumor activity and a distinct tubulin site,” Proceedings of the American Association for Cancer Research Annual Meeting, 48:337 (2007).
Bacher Gerald
Beckers Thomas
Bruyneel Erik
Emig Peter
Engel Jürgen
Anderson James D
Marschel Ardin
Ropes & Gray LLP
ZIOPHARM Oncology, Inc.
LandOfFree
Indolyl-3-glyoxylic acid derivatives having therapeutically... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolyl-3-glyoxylic acid derivatives having therapeutically..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolyl-3-glyoxylic acid derivatives having therapeutically... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4030929